Allergic Reaction to Depot Risperidone but Not to Oral Risperidone
J Clin Psychiatry 2005;66(7):949-949 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.
Oral risperidone is an effective and well-tolerated atypical
antipsychotic1 that has been in widespread clinical usage for
over 10 years. In recent years, a long-acting injectable form of
depot risperidone with a delivery system different from other
depot antipsychotics became available in the United States
following several years of marketing in other countries. This
formulation consists of risperidone microencapsulated in 7525
polylactide-co-glycolide (PLG) at a concentration of 381 mg
of risperidone per gram of microspheres2
; the PLG slowly hydrolyzes
to release risperidone, allowing administration every